keyword
MENU ▼
Read by QxMD icon Read
search

breast tumor

keyword
https://www.readbyqxmd.com/read/29228411/management-of-breast-cancer-in-adjuvant-chemotherapy-settings-in-the-kanagawa-breast-oncology-group
#1
Mayako Terao, Naoki Niikura, Yasuhiro Suzuki, Norihiko Sengoku, Hitoshi Arioka, Takashi Ishikawa, Koichiro Tsugawa, Yutaka Tokuda
OBJECTIVE: Many different options for adjuvant chemotherapy are recommended in guidelines for the treatment of breast cancer. Therapeutic strategies vary among physicians. The major goals for this project were to gain a better understanding of how biomarkers are integrated into practice and how physicians select adjuvant chemotherapy. METHODS: We assembled a questionnaire with 23 example scenarios of breast cancer cases, including 6 items relevant to postoperative adjuvant therapy...
December 20, 2017: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/29228315/comparison-of-neoadjuvant-nab-paclitaxel-carboplatin-vs-nab-paclitaxel-gemcitabine-in-triple-negative-breast-cancer-randomized-wsg-adapt-tn-trial-results
#2
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Nikola Bangemann, Christoph Lindner, Sherko Kuemmel, Michael Clemens, Jochem Potenberg, Peter Staib, Andreas Kohls, Raquel von Schumann, Ronald Kates, Ronald Kates, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck
Background: Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results in higher pCR rates with uncertain survival impact. We evaluated carboplatin vs gemcitabine with a nab-paclitaxel backbone as a short 12-week A-free regimen with a focus on early response. Methods: Patients with TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor receptor 2-negative, cT1c-cT4c, cN0/+) were randomly assigned to A: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w); vs B: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w...
December 8, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29228296/paqr4-has-a-tumorigenic-effect-in-human-breast-cancers-in-association-with-reduced-cdk4-degradation
#3
Huanhuan Zhang, Ruomei Han, Zhi-Qiang Ling, Fuyuan Zhang, Yongfan Hou, Xue You, Meiqin Huang, Zilong Zhao, Zhenzhen Wang, Yan Chen
Progestin and AdipoQ Receptor 4 (PAQR4) is a member of the PAQR family and the members within this family are involved in the regulation of a number of biological processes including metabolism and cancer development. The potential function of PAQR4 in human cancers is unknown. Analysis of ONCOMINE database reveals that PAQR4 is highly expressed in human breast cancers. We confirmed this finding by analyzing 82 human breast cancers samples. PAQR4 mRNA level was robustly upregulated in human breast cancer samples compared with their corresponding para-cancerous histological normal tissues (P < 0...
December 8, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/29227748/survival-in-signet-ring-cell-carcinoma-varies-based-on-primary-tumor-location-a-surveillance-epidemiology-and-end-results-database-analysis
#4
San-Gang Wu, Xue-Ting Chen, Wen-Wen Zhang, Jia-Yuan Sun, Feng-Yan Li, Zhen-Yu He, Xiao-Qing Pei, Qin Lin
BACKGROUND: The aim of this study was to investigate the survival of patients with signet ring cell carcinoma (SRCC) based on primary tumor location. METHODS: Patient data were obtained from the Surveillance, Epidemiology, and End Results database (1988-2012) with ≥200 cases per tumor location. Cox regression analysis was used to investigate prognostic factors of cause-specific survival (CSS). RESULTS: We identified 24,171 patients. Of the patients, 63...
December 11, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29227654/synergistic-chemopreventive-and-therapeutic-effects-of-co-drug-ua-met-implication-in-tumor-metastasis
#5
Guirong Zheng, Zhichun Shen, Aixiao Xu, Kai Jiang, Pengyu Wu, Xiang Yang, Xian Chen, Jingwei Shao
The anticancer properties of ursolic acid (UA) and metformin (Met) have been well demonstrated. However, whether these compounds can act synergistically to prevent and treat cancer is not known. We present in this study, the synergism between UA and Met, and that of a new codrug made of UA and Met (UA-Met) against several cancer cell lines. The combination of high concentration of UA (25, 50, 75, 100 μM) and Met (5, 10, 20, 40 mM) resulted in synergetic cytotoxicity on MDA-MB-231 and MCF-7 cells (CI < 0...
December 11, 2017: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/29227648/quinazolinone-based-anticancer-agents-synthesis-anti-proliferative-sar-anti-tubulin-activity-and-tubulin-co-crystal-structure
#6
Wolfgang Dohle, Fabrice L Jourdan, Gregory Menchon, Andrea E Prota, Paul A Foster, Pascoe Mannion, Ernest Hamel, Mark P Thomas, Philip G Kasprzyk, Eric Ferrandis, Michel O Steinmetz, Mathew P Leese, Barry V L Potter
Quinazolinone-based anti-cancer agents were designed, decorated with functional groups from a 2-methoxyestradiol-based microtubule disruptor series, incorporating the aryl sulfamate motif of steroid sulfatase (STS) inhibitors. The steroidal AB-ring system was mimicked, favoring conformations with an N-2 substituent occupying D-ring space. Evaluation against breast and prostate tumor cell lines identified 7b with DU-145 anti-proliferative activity (GI50 300 nM). A preliminary structure-activity relationship afforded compounds (e...
December 11, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29227553/fluorescence-lifetime-imaging-of-a-caspase-3-apoptosis-reporter
#7
Johanna M Buschhaus, Anne E Gibbons, Kathryn E Luker, Gary D Luker
Caspase-3 is a proteolytic enzyme that functions as a key effector in apoptotic cell death. Determining activity of caspase-3 provides critical information about cancer cell viability and response to treatment. To measure apoptosis in intact cells and living mice, a fluorescence imaging reporter that detects caspase-3 activity by Förster resonance energy transfer (FRET) was used. Changes in FRET by fluorescence lifetime imaging microscopy (FLIM) were measured. Unlike FRET measurements based on fluorescence intensity, lifetime measurements are independent of reporter concentration and scattering of light in tissue, making FLIM a robust method for imaging in 3D environments...
December 11, 2017: Current Protocols in Cell Biology
https://www.readbyqxmd.com/read/29227350/tamoxifen-retinopathy-during-treatment-of-an-inoperable-desmoid-tumor
#8
Meredith Furst, Marie B Somogyi, Robert W Wong, Dejka Araujo, Clio A Harper
PURPOSE: To evaluate the clinical significance and rarity of tamoxifen retinopathy after a long-term tamoxifen treatment for an inoperable desmoid tumor. METHODS: Case report. RESULTS: Tamoxifen retinopathy is a condition rarely observed in clinical practice. Although tamoxifen is typically a treatment for breast cancer patients, we present a 68-year-old woman taking tamoxifen for an inoperable desmoid tumor, an equally rare condition. She presented with bilaterally deteriorating vision over the course of a year...
December 8, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29227346/surgical-resection-of-the-primary-tumor-in-women-with-de-novo-stage-iv-breast-cancer-contemporary-practice-patterns-and-survival-analysis
#9
Whitney O Lane, Samantha M Thomas, Rachel C Blitzblau, Jennifer K Plichta, Laura H Rosenberger, Oluwadamilola M Fayanju, Terry Hyslop, E Shelley Hwang, Rachel A Greenup
OBJECTIVE: We evaluated patterns of surgical care and their association with overall survival among a contemporary cohort of women with stage IV breast cancer. BACKGROUND: Surgical resection of the primary tumor remains controversial among women with stage IV breast cancer. METHODS: Women diagnosed with clinical stage IV breast cancer from 2003 to 2012 were identified from the American College of Surgeons National Cancer Database. Those with intact primary tumors who were alive 12 months after diagnosis were categorized by treatment sequence: (1) surgery before systemic therapy, (2) systemic therapy before surgery, and (3) systemic therapy alone...
December 7, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/29227302/the-target-invites-a-foe-antibody-drug-conjugates-in-gynecologic-oncology
#10
Maira P Campos, Gottfried E Konecny
PURPOSE OF REVIEW: Antibody-drug conjugates (ADCs) represent a promising new class of cancer therapeutics. Currently more than 60 ADCs are in clinical development, however, only very few trials focus on gynecologic malignancies. In this review, we summarize the most recent advances in ADC drug development with an emphasis on how this progress relates to patients diagnosed with gynecologic malignancies and breast cancer. RECENT FINDINGS: The cytotoxic payloads of the majority of the ADCs that are currently in clinical trials for gynecologic malignancies or breast cancer are auristatins (MMAE, MMAF), maytansinoids (DM1, DM4), calicheamicin, pyrrolobenzodiazepines and SN-38...
December 8, 2017: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29227280/proapoptotic-puma-targets-stem-like-breast-cancer-cells-to-suppress-metastasis
#11
Qi Sun, Jacqueline Lesperance, Hiromi Wettersten, Elaine Luterstein, Yoko S DeRose, Alana Welm, David A Cheresh, Jay S Desgrosellier
Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients' tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemness...
December 11, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29227250/oncoplastic-surgery-of-multicentric-multifocal-breast-cancer-case-report
#12
I Kokhreidze
The multicentric/multifocal form of breast cancer has been considered as relative contraindicationfor breast conserving surgery. According to the results of the studies conducted in the last century, the local recurrence rate of the disease after breast conserving surgeries of multicentric/multifocal breast cancer exceeds 40%. Thus these data were considered as main argument for mastectomy advocates, as non-alternative surgical treatment in these cases. Wide clinical application of oncoplastic surgical techniques gave us possibilities to resolve dilemma: excise tumor - containing quadrant with achieving clear margins and satisfactory cosmetic outcome, without increasing risk of disease-related complications...
November 2017: Georgian Medical News
https://www.readbyqxmd.com/read/29226682/first-evaluation-of-radioiodinated-flavonoids-as-necrosis-avid-agents-and-application-in-the-early-assessment-of-tumor-necrosis
#13
Jiajia Liang, Ziping Sun, Dongjian Zhang, Qiaomei Jin, Lingqiao Cai, Lin Ma, Wei Liu, Yicheng Ni, Jian Zhang, Zhiqi Yin
A rapid and accurate identification of necrotic tissues is of great importance to define disease severity, predict prognosis and monitor responses to therapies. To seek necrosis-avid agents with clinically translational potential, we first evaluated the necrosis avidity of flavonoids in rodent models of muscular, myocardial and tumoral necrosis. In this study, the necrosis avidity of eight radioiodinated 5,7-dihydroxyflavones was tested by ex vivo gamma counting, histochemical staining, and autoradiography in mouse models of ethanol-induced muscular necrosis...
December 11, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29226332/preoperative-prediction-nomogram-based-on-primary-tumor-mirnas-signature-and-clinical-related-features-for-axillary-lymph-node-metastasis-in-early-stage-invasive-breast-cancer
#14
Xinhua Xie, Weige Tan, Bo Chen, Xiaojia Huang, Cheng Peng, Shumei Yan, Lu Yang, Cailu Song, Jianwei Wang, Wenbo Zheng, Hailin Tang, Xiaoming Xie
More than half patients who undergo axillary lymph node (ALN) surgery are ALN negative in early-stage invasive breast cancer (EIBC). Thus, to avoid excessive treatment, we aim to establish and validate a novel nomogram model for the preoperative diagnosis of ALN status in patients with EIBC. In total, 864 patients with EIBC from two independent centers were enrolled in our study. For the discovery set, miRNAs expression profiling with functional roles in ALN metastasis were discovered by microarray analysis and validated by quantitative polymerase chain reaction (PCR)...
December 11, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29225779/risk-of-solid-cancer-in-patients-with-mast-cell-activation-syndrome-results-from-germany-and-usa
#15
Gerhard J Molderings, Thomas Zienkiewicz, Jürgen Homann, Markus Menzen, Lawrence B Afrin
Background:  It has been shown repeatedly that mast cells can promote or prevent cancer development and growth. If development and/or progression of a solid cancer is substantially influenced by mast cell activity, the frequencies of occurrence of solid cancers in patients with primary mast cells disorders would be expected to differ from the corresponding prevalence data in the general population. In fact, a recent study demonstrated that patients with systemic mastocytosis (i.e., a rare neoplastic variant of the primary mast cell activation disease) have increased risk for solid cancers, in particular melanoma and non-melanoma skin cancers...
2017: F1000Research
https://www.readbyqxmd.com/read/29225623/ki-67-expression-by-immunohistochemistry-and-quantitative-real-time-polymerase-chain-reaction-as-predictor-of-clinical-response-to-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#16
Prihantono Prihantono, Mochammad Hatta, Christian Binekada, Daniel Sampepajung, Haryasena Haryasena, Berti Nelwan, Andi Asadul Islam, Andi Nilawati Usman
Background: Chemotherapy has become a standard of treatment in managing breast cancer. To achieve proper treatment for the right patients, the predictive marker is needed. Ki-67 is a biomarker of proliferation for solid tumor. Studies mentioned association of Ki-67 expression with chemotherapy response. The study aims are to evaluate whether Ki-67 expression detected by immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) may predict clinical response to neoadjuvant chemotherapy in breast cancer...
2017: Journal of Oncology
https://www.readbyqxmd.com/read/29225137/valproic-acid-a-histone-deacetylase-inhibitor-induces-apoptosis-in-breast-cancer-stem-cells
#17
Nazlıhan Aztopal, Merve Erkisa, Elif Erturk, Engin Ulukaya, Asuman Hatice Tokullugil, Ferda Ari
Cancer stem-like cells (CSCs) are a cell subpopulation that can reinitiate tumors, resist chemotherapy, give rise to metastases and lead to disease relapse because of an acquired resistance to apoptosis. Especially, epigenetic alterations play a crucial role in the regulation of stemness and also have been implicated in the development of drug resistance. Hence, in the present study, we examined the cytotoxic and apoptotic activity of valproic acid (VPA) as an inhibitor of histone deacetylases (HDACs) against breast CSCs (BCSCs)...
December 7, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/29224780/a-living-biobank-of-breast-cancer-organoids-captures-disease-heterogeneity
#18
Norman Sachs, Joep de Ligt, Oded Kopper, Ewa Gogola, Gergana Bounova, Fleur Weeber, Anjali Vanita Balgobind, Karin Wind, Ana Gracanin, Harry Begthel, Jeroen Korving, Ruben van Boxtel, Alexandra Alves Duarte, Daphne Lelieveld, Arne van Hoeck, Robert Frans Ernst, Francis Blokzijl, Isaac Johannes Nijman, Marlous Hoogstraat, Marieke van de Ven, David Anthony Egan, Vittoria Zinzalla, Jurgen Moll, Sylvia Fernandez Boj, Emile Eugene Voest, Lodewyk Wessels, Paul Joannes van Diest, Sven Rottenberg, Robert Gerhardus Jacob Vries, Edwin Cuppen, Hans Clevers
Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, pathologically, and clinically. Here, we describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic BC organoid lines were generated, broadly recapitulating the diversity of the disease. BC organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. DNA copy number variations as well as sequence changes were consistent within tumor-organoid pairs and largely retained even after extended passaging...
December 5, 2017: Cell
https://www.readbyqxmd.com/read/29224274/-correlation-analysis-of-pd-l1-expression-and-prognosis-in-triple-negative-breast-cancers
#19
B J Pan, C Xu, G Q Ping, G X Song, W M Zhang, C Wang, Z H Zhang
Objective: To investigate the relationship between PD-L1 expression and the clinicopathologic features and prognosis in triple-negative breast carcinomas (TNBC). Methods: All 142 cases of TNBC were collected from the First Affiliated Hospital of Nanjing Medical University from February 2011 to December 2014, and the surgical excision or biopsy specimens from patients without chemotherapy and radiotherapy were included. Histopathologic analysis of stromal tumor infiltrating lymphocyte (sTIL) was performed on HE sections, and PD-L1 immunohistochemical staining was done with MaxVision...
December 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29223745/buparlisib-plus-fulvestrant-in-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-progressing-on-or-after-mtor-inhibition-belle-3-a-randomised-double-blind-placebo-controlled-phase-3-trial
#20
Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per E Lønning, Wolfgang Janni, Ruth O'Regan, Marie-Ange Mouret-Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C G Tjan-Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT phosphorylation via a feedback activation pathway, potentially leading to resistance to mTOR inhibitors. We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrine therapy and mTOR inhibitors...
December 6, 2017: Lancet Oncology
keyword
keyword
31630
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"